Clinical effect of Tripterygium Glycoside Tablets in treating Sjogren′s syndrome
JU Yanjuan1 LI Rongping1 ZHOU Shenghui2 HU Jin2 GUO Dibin1▲
1.Department of Rheumatology and Immunology,the First Affiliated Hospital of Gannan Medical College,Jiangxi Province,Ganzhou 341000,China;
2.Department of Emergency,Shangyou County Hospital of Traditional Chinese Medicine,Jiangxi Province,Shangyou 341200,China
Abstract：Objective To explore the clinical effect of Tripterygium Glycoside Tablets in the treatment of Sjogren′s syndrome.Methods From January 2020 to May 2021,60 patients with Sjogren′s syndrome admitted to the First Affiliated Hospital of Gannan Medical College were selected as the research objects,and they were divided into the control group (30 cases) and the observation group (30 cases) according to the random number table method.The control group was treated with Prednisone+Hydroxychloroquine Sulfate,and the observation group was treated with Tripterygium Glycoside Tablets.The clinical efficacy,the levels of immunoglobulin,rheumatoid factor,improvement of clinical symptoms,and the incidence of adverse reactions between the two groups were compared.Results The clinical efficacy of the observation group was higher than that of the control group,and the difference was statistically significant (P＜0.05).After treatment,the levels of IgG and rheumatoid factor (RF) in the observation group were lower than those in the control group,and the differences were statistically significant (P＜0.05).The saliva flow rate and tear flow rate of the observation group were higher than those of the control group,and the numerical evaluation scale (NRS) score of the observation group was lower than that of the control group,the differences were statistically significant (P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion Tripterygium Glycoside Tablets are effective in treating Sjogren′s syndrome.They can effectively improve the symptoms of dry mouth,dry eyes,and joint pain,as well as immune function and rheumatoid factor levels.
Narain S，Berman N，Furie R.Biologics in the treatment of Sjogren′s syndrome，systemic lupus erythematosus，and lupus nephritis[J].Curr Opin Rheumatol，2020，32（6）：609-616.
[8]
Sisto M，Barca A，Lofrumento DD，et al.Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjogren′s syndrome and its regulation by the ubiquitin-editing enzyme A20[J].Clin Exp Immunol，2016，184（2）：183-196.
京公网安备 11010502046607号